Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
NCT04657939 on ClinicalTrials.gov · last registry update 2023-02-27
Finished 31 October 2022, after enrolling 57 people. Primary outcome, as filed: Change in myocardial perfusion after treatment. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- University of Leeds
- Sponsor type
- Other
- Enrollment
- 57
- Started
- 2020-12-01
- Primary completion
- 2022-10-31 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in myocardial perfusion after treatment
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.